DNA ligase IV mediated inhibitor of NHEJ (non-homologous end joining) that increases the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells up to 19-fold.

Note: Axon Medchem confirmed that the active chemical entity of SCR7, as described by Srivastava and others, is actually SCR7 pyrazine (Axon 2531). Careful application of the synthetic conditions described in this paper and comparison with authentic SCR7 pyrazine reveals identical chemical products.

KEYWORDS: SCR7 pyrazine | supplier | NHEJ/DNA ligase IV inhibitor | CAS [14892-97-8] | [67648-82-2] | [1538566-74-3] | DNA-RNA | DNA ligase | Inhibitor | Non-homologous end joining | CRISPR | Cas9 | DSB | double strand breaks | DNA repair | tumor progression